Compare Cytokinetics Inc (CYTK) vs Marsh & McLennan Companies, Inc. (MRSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Marsh & McLennan Companies, Inc. — how do they compare? Cytokinetics Inc trades at $62.72 (market cap $8.62B), while Marsh & McLennan Companies, Inc. trades at $176.15 (market cap $84.31B). The key difference: Marsh & McLennan Companies, Inc. is far larger — about 9.8× Cytokinetics Inc's market cap, and Marsh & McLennan Companies, Inc. pays a 2.24% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Marsh & McLennan Companies, Inc. for 109 Days on average.
| CYTK | MRSH | |
|---|---|---|
Market Cap | $8.62B | $84.31B |
Volume | 2,594,626 | 3,948,947 |
Sector | Health | Financials |
52-Week High | $87.26 | $207.02 |
52-Week Low | $54.76 | $157.32 |
Typical Hold Time | 19 Days | 109 Days |
Enterprise Value | $8.72B | $104.99B |
Dividend Yield | — | 2.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $62.48, up 2.23% today, but faces bearish technical signals with 18 sell indicators versus 4 buy signals. The company shows strong revenue growth potential with recent positive Phase 3 trial results for aficamten in non-obstructive HCM, though it operates at significant losses with a -1,321% net income margin. Cash flow remains heavily dependent on financing activities, with operating cash flow negative at -$555 million in 2026.
Wall Street maintains strong bullish sentiment with 97% buy ratings and a $112.60 consensus price target, representing 80% upside potential. Key risks include continued cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization of pipeline drugs. The stock's valuation appears stretched at 114x sales given current financial performance.
Marsh (MRSH) trades at $173.66, up 1.11% today, with a bullish technical signal despite mixed moving averages and oscillators. The company shows strong fundamentals, with revenue growing to $26.98B in 2025 and net income of $4.16B, supported by consistent earnings beats. Recent news highlights the completion of the Accel Holdings acquisition, potentially enhancing its advisory services footprint. Valuation ratios include a P/E of 21.57 and ROE of 25.72%, indicating solid profitability.
The outlook for MRSH is positive, driven by earnings momentum and strategic acquisitions, but risks include high debt levels and competitive pressures. Analysts maintain a consensus price target of $202.71, suggesting upside potential, though the majority recommend Hold. Investors should weigh growth opportunities against execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →
